PDE4A and familial dilated cardiomyopathy: Here we present the study rationale and design of Regeneration in Cervical Degenerative Myelopathy (RECEDE-Myelopathy), the first regenerative medicine trial for degenerative cervical myelopathy (DCM), which aims to test disease-modulating activity of the phosphodiesterase (PDE)3/PDE4 inhibitor Ibudilast as an adjuvant to surgical decompression.